| Host: |
HEK293 |
| Note: |
STRICTLY FOR FURTHER RESEARCH USE ONLY (RUO). MUST NOT TO BE USED IN DIAGNOSTIC OR THERAPEUTIC APPLICATIONS. |
| Short Description: |
Recombinant-Human CD40 (TNFRSF5)-protein was developed from hek293. For use in research applications. |
| Conjugation: |
Unconjugated |
| Formulation: |
Lyophilised from 0.2 Mu m filtered PBS solution, pH7.2, 5% Trehalose. |
| Storage Instruction: |
Can be stored in working aliquots at 2°C-8°C C for one month, or at-20°C to-70°C for 1 year. Avoid repeated freeze/thaw cycles. NA |
| Endotoxin: |
Endotoxin content was assayed using a LAL gel clot method. Endotoxin level was found to be less than 0.1 ng/µg (1EU/µg). NA |
| Immunoreactivity: |
The activity was tested by the ability of immobilized recombinant human CD40 to bind Human CD40 Ligand with a linear range of 10-500 ng/ml NA |
| Gene Symbol: |
CD40 |
| Gene ID: |
958 |
| Uniprot ID: |
TNR5_HUMAN |
| Immunogen Region: |
ECD |
| Immunogen: |
Optimized DNA sequence encoding extracellular domain of Human CD40 including a C-terminal His tag was expressed in HEK293 cells. NA |
| Tissue Specificity | B-cells and in primary carcinomas. |
| Function | Receptor for TNFSF5/CD40LG. Transduces TRAF6- and MAP3K8-mediated signals that activate ERK in macrophages and B cells, leading to induction of immunoglobulin secretion. |
| Protein Name | Tumor Necrosis Factor Receptor Superfamily Member 5B-Cell Surface Antigen Cd40Bp50Cd40l ReceptorCdw40Cd Antigen Cd40 |
| Database Links | Reactome: R-HSA-198933 P25942-1Reactome: R-HSA-5668541 P25942-1Reactome: R-HSA-5676594 P25942-1 |
| Cellular Localisation | Isoform I: Cell MembraneSingle-Pass Type I Membrane ProteinIsoform Ii: Secreted |
| Alternative Protein Names | Tumor Necrosis Factor Receptor Superfamily Member 5 proteinB-Cell Surface Antigen Cd40 proteinBp50 proteinCd40l Receptor proteinCdw40 proteinCd Antigen Cd40 proteinCD40 proteinTNFRSF5 protein |
Information sourced from Uniprot.org
12 months for antibodies. 6 months for ELISA Kits. Please see website T&Cs for further guidance
